Neuropsychopharmacology Reports
March 1, 2023
Yuji Masataka, Takeshi Sugiyama, Yoshiyuki Akahoshi et al.
To determine the risk factors for cannabis use disorders and cannabis psychosis in Japan based on a 2021 online survey among Japanese users of social network services. The 3142 respondents who had used cannabis within the preceding year were categorized into two groups based on the development of cannabis use disorder and/or cannabis psychosis. Analyses were performed to determine these...
Neuropsychopharmacology Reports
September 7, 2020
Toshihiko Matsumoto, Toshitaka Kawabata, Kyoji Okita et al.
9 citations
AIM: The objective of the current study was to identify risk factors that affect the onset of dependence and chronic psychosis due to cannabis use. METHODS: We examined clinical genetic factors, psychiatric disorders prior to cannabis use, starting age of cannabis use, duration and frequency of cannabis use, types of cannabis products used, combined use of other psychoactive substances, and the...
Psychiatry and Clinical Neurosciences
April 1, 2008
Miho Miyajima, Toshihiko Matsumoto, Shigeo Ito
45 citations
DESIGNER DRUG ABUSE is a serious problem in Japan.1 Recently we encountered an acute intoxication in an emergency setting involving one such drug, which has never been reported as a clinical case anywhere. A 40-year-old man, with no previous history of mental disorder, although having had experiences of occasional use of street drugs, was brought to the emergency room by his mother. He was in a...
Addiction
October 10, 2006
Toshihiko Matsumoto, Takayuki Okada
29 citations
'Foxy' is a widely used street name for a hallucinogenic drug containing the tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). The US Drug Enforcement Administration classified 5-MeO-DIPT as a Schedule I substance in 2004 [1]; the Japanese Ministry of Health, Labour and Welfare has also restricted this substance since April 2005, according to the Narcotics and...